drugset / Trial / NCT01860807
Trial of Ibudilast for Methamphetamine Dependence
Phase 2
Completed
125 enrolled
University of California, Los Angeles
National Institute on Drug Abuse (NIDA) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The objective of this study is to test the safety and potential efficacy of ibudilast to treat methamphetamine dependence. The study hypotheses are that ibudilast will reduce methamphetamine use and increase treatment retention more than placebo among patients seeking treatment for methamphetamine dependence. As HIV infection is a common complication of methamphetamine dependence, half of the participants will be HIV positive and the study will assess whether ibudilast also improves HIV related outcomes (e.g. medication adherence, CD4 count, risk behaviors).
Timeline
- Start
- 2013-07
- Primary completion
- 2017-12-31
- Completion
- 2017-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibudilast | Small molecule | 50 mg | — |